Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

Journal of Clinical Pathology

Volumn 63, Issue 2, 2010, Pages 169-173

  Kelly, Paul J ^a   Archbold, Pooler ^b   Price, John H ^b   Cardwell, Chris ^a   McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CYSTADENOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CYSTADENOMA, MUCINOUS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; YOUNG ADULT;

EID: 77349093587     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.072355     Document Type: Article

References (41)

1. Ballesta A, Molina R. Tumor markers: definitions and classification. Torino: Edizioni Minerva Medica, 1993.
2. Bast RC Jr, Xu FJ, Yu YH, et al. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87.
3. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
4. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995;76:2092-6.
5. Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44:147-54.
6. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
7. Donaldson ES, van Nagell JR Jr, Pursell S, et al. Multiple biochemical markers in patients with gynecologic malignancies. Cancer 1980;45:948-53.
8. Motoyama T, Watanabe H, Takeuchi S, et al. Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. Cancer 1990;66:2628-35.
9. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 2003;58:667-72.
10. Canney PA, Wilkinson PM, James RD, et al. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125. Br J Cancer 1985;52:131-3.
11. Dede M, Gungor S, Yenen MC, et al. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 2006;16:189-93.
12. Dong L, Cui H, Li XP, et al. Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients. Zhonghua Fu Chan Ke Za Zhi 2008;43:5-8.
13. Kudoh K, Kikuchi Y, Kita T, et al. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest 1999;47:52-7.
14. Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 1996;62:67-72.
15. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59:111-6.
16. Ye C, Ito K, Komatsu Y, et al. Extremely high levels of CA19-9 and CA125 antigen in benign mucinous ovarian cystadenoma. Gynecol Oncol 1994;52:267-71.
17. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005;24:4-25.
18. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000;24:1447-64.
19. Lerwill M, Young R. Mucinous tumours of the ovary. Diagn Histopathol 2008;14:366-87.
20. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63.
21. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004;28:1311-18.
22. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002;26:139-52.
23. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer 1988;61:340-8.
24. Saygili U, Uslu T, Erten O, et al. Borderline ovarian tumours: retrospective analysis of twenty-one cases. Eur J Gynaecol Oncol 1998;19:182-5.
25. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002;26:1529-41.
26. Siriaunkgul S, Robbins KM, McGowan L, et al. Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol 1995;14:198-208.
27. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-71.
28. Kudlacek S. Tumor markers. Their current diagnostic status. Wien Med Wochenschr 1988;138:228-42.
29. Touitou Y, Bogdan A. Critical study of current tumoral markers. Bull Cancer 1988;75:247-62.
30. Gocze PM, Szabo DG, Than GN, et al. Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors. Gynecol Obstet Invest 1988;25:268-72.
31. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 1992;69:2131-42.
32. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
33. Ayhan A, Guven S, Guven ES, et al. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 2007;86:484-90.
34. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
35. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999;23:617-35.
36. Fleuren GJ, Nap M, Aalders JG, et al. Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer 1987;60:2437-42.
37. Nucci MR, Castrillon DH, Bai H, et al. Biomarkers in diagnostic obstetric and gynecologic pathology: a review. Adv Anat Pathol 2003;10:55-68.
38. Scully RE, Young R, Clement P. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Washington: Armed Forces Institute of Pathology, 1998.
39. Nishikawa A, Fukushima M, Shimano S, et al. A case of metaplastic Brenner tumor with elevated serum CA19-9 levels. Nippon Sanka Fujinka Gakkai Zasshi 1990;42:1579-82.
40. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
41. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.